Jin Jun Luo, William Wallace, and John W. Kusiak
Abstract
The FDA approved a new drug: lecanemab (or BAN2401, brand name Leqembi, Biogen and Eisai) for treating Alzheimer’s disease (AD) on January 6th, 2023, under the accelerated approval pathway. The approval was based on the results from a phase 2 clinical trial and part of a phase 3 trial (Clarity AD) showing a reasonable likelihood of clinical benefits [1, 2]. This approval is acclaimed as a breakthrough in treating patients with early AD because of its disease modifying effect.
Published on: February 26, 2023
doi: 10.17756/jnen.2023-101
Citation: Luo JJ, Wallace W, Kusiak JW. 2023. Disease Modification Therapy with Anti-Soluble Aβ Protofibril Antibody for Alzheimer Disease. J Neurol Exp Neurosci 9(1): 4-6.
doi: 10.17756/jnen.2023-101
Citation: Luo JJ, Wallace W, Kusiak JW. 2023. Disease Modification Therapy with Anti-Soluble Aβ Protofibril Antibody for Alzheimer Disease. J Neurol Exp Neurosci 9(1): 4-6.
671
Downloads
Downloads